Page 13 - Eceptor News Today

Study in the International Journal of Obesity reveals that BMAL1 deletion in mice protects against obesity and non-alcoholic fatty liver disease caused by a high-fat diet, highlighting its potential as a therapeutic target.

Infants born to women with pre-gestational type 2 diabetes who take second-line non-insulin antidiabetic medications (ADMs) during pregnancy are at no higher risk of major congenital malformations (MCMs) than infants born to those who take insulin, according to a new study led by Harvard T.H. Chan School of Public Health.

For decades, scientists have noted an intriguing similarity between a deficiency in vitamin B12 – an essential nutrient that supports healthy development and functioning of the central nervous system (CNS) – and multiple sclerosis (MS), a chronic disease in which the body's immune system attacks the CNS and which can produce neurodegeneration.

Study finds that the anti-obesity medication tirzepatide effectively maintains weight loss in obese adults, offering a promising approach to managing obesity and related health complications.

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

Transcranial photobiomodulation (tPBM) treatment affected insulin therapy on microglial function.

Research reveals that T cell migration relies on ion and water influx for actin polymerization and movement, with the WNK1 kinase playing a critical role in regulating these processes, offering new insights into adaptive immunity.

Researchers at Case Western Reserve University and University Hospitals have identified an enzyme that blocks insulin produced in the body-;a discovery that could provide a new target to treat diabetes.

Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective.